OXBDF News and Press, Oxford BioMedica From 04/26/19

In February I wrote about Axovant Gene Therapies Ltd ( AXGT ), formerly Axovant Sciences ( AXON-OLD ), providing my thoughts on data expected in March 2019 from two of the company's trials, one in Parkinson's disease and one in GM2 gangliosidosis. I believed it was too early to recommend a l...

Oxford BioMedica PLC (OXBDF) Q4 2018 Earnings Conference Call March 14, 2019 8:00 AM ET Company Participants Catherine Isted – Head-Corporate Development and IR John Dawson – Chief Executive Officer Stuart Paynter – Chief Financial Officer Conference Call ...

Oxford BioMedica plc ( OTCPK:OXBDF ): FY GAAP EPS of 10.89p. More news on: Oxford BioMedica plc, Earnings news and commentary, Tech stocks news, Read more ...

Axovant Sciences Ltd ( AXON ) is approaching two key catalysts which may attract the attention of the markets. When I last wrote about the company , I noted that I didn't like the decisions being made at AXON. Throughout 2019 we may begin to see if the company's risky decision, to pivot into ...

For a good chunk of 2018, the UK's equity markets were under the cosh, and index prices fell across the board. But, since the start of this year, there's been a sense of optimism around. Political and economic uncertainties aside, the FTSE All-Share has managed a 6.8 percent gain in recent wee...

The following slide deck was published by Oxford Biomedica PLC in conjunction with their 2018 Q2 earnings Read more ...

Oxford Biomedica PLC ( OTCPK:OXBDF ): 1H EPS of 7.56p More news on: Oxford Biomedica PLC, Earnings news and commentary, Tech stocks news, , Read more ...

On July 10th 2018 Axovant Sciences ( AXON ) announced a partnership with Benitec Biopharma ( BNTC ) for exclusive global rights to BB-301, now named AXO-AAV-OPMD, for the treatment of oculopharyngeal muscular dystrophy, or OPMD, and five additional gene therapy programs in neurological di...

Voyager Therapeutics ( VYGR ) is a clinical-stage gene therapy company focused on developing treatments for patients suffering from severe neurological diseases using an adeno-associated virus, or AAV, gene therapy approach, that either increases or decreases the production of a specific prote...

The purpose of this article is to take an in-depth look at Axovant Sciences' ( AXON ) Parkinson's gene therapy which was briefly touched on in my previous article . Parkinson's disease Parkinson’s is a chronic, progressive and debilitating neurodegenerative resulting in the loss o...